이상의 결과를 종합하면, 혼합유산균 2종(Bifidobacterium animalis ssp. Lactis Bf141와 Lactobacillus rhamnosus Lb102)의 섭취는 고지방식이 유도 비만 마우스에서 체중, 체지방, 제지방, 골밀도 등 주요 체성분에 영향을 주지 않았다. 혼합유산균은 식욕 조절 효과를 위해 측정한 사료 섭취량에도 영향을 주지 않았으며, 간 조직 무게에도 영향을 미치지 않았다. 인슐린저항성과 포도당신생합성의 주요 지표인 공복혈당량 또한 혼합유산균 급여에 의해 변화 하지 않았다. 또한 혼합유산균은 심혈관질환의 지표로 사용되는 혈중 중성지방 및 총 콜레스테롤에 영향을 주지 않았으며, 체내 지방의 소화 및 흡수율에서도 영향을 미치지 않았다. 결론적으로, 고지방식이유도 비만 마우스를 이용하여 혼합유산균(Bf141 + Lb102)의 항비만 생리활성 을 검증한 결과, 유의미한 물리적, 대사적 표현형 개선은 검증되지 않았다. 따라서, 추후 개별 보다 다양한 혼합 조건 및 농도로 연구를 설계하여 혼합유산균의 항비만 효과를 검증할 필요성이 있다.

This study was conducted to investigate the anti-obesity effect of Discorea Japonica Thunb. fermented with Monascus After inducing obesity by feeding hight fat diet (diet induced obesity model: DIO) for four weeks, each 8 rats were assigned to normal (Nor), high fat diet (HF), high fat diet containing orlistat (PC), high fat diet containing different concentration of Discorea Japonica Thunb. fermented with Monascus (UPDM_L, UPDM_H) and Discorea Japonica Thunb. (UPD) extract. Although the UPD, UPDM_L (ultrafine pulverized Discorea Japonica Thunb. fermented with Monascus: 400 mg/kg) and UPDM_H (DIO oral administration ultrafine pulverized Discorea Japonica Thunb. fermented with Monascus: 800 mg/kg) showed weight gain inhibition effects, the results of poor obesity inhibition rather than PC were confirmed. However, it showed a more effective weight loss effect in UPDM_H than UPD, and significantly reduced the weight of epididymal fat and subcutaneous fat. Furthermore, the possibility of anti-obesity effects of Discorea Japonica Thunb. fermented with Monascus can be confirmed by observing the effects of reducing serum total cholesterol, triglyceride and LDL concentrations, reducing ALT and AST levels, and inhibiting fat build-up in liver tissue. It is believed that Discorea Japonica Thunb. fermented with Monascus can be expected to utilize as a functional material that is important to improve anti-obesity and metabolic syndrome.

This study was designed to evaluate the effect of administering dietary tomato powder (TP; 1, 5, and 10%) to mice with high-fat diet (HFD)-induced obesity for 12 weeks. The TP used in this study was prepared using unmarketable tomatoes. Male C57BL/6J mice (n=60) were randomly divided into five groups, namely, CON, mice fed a basal diet (10% fat); HFD, mice fed HFD (60% fat); HFD+TP1, mice fed HFD (60% fat) supplemented with 1% TP; HFD+TP5, mice fed HFD (60% fat) supplemented with 5% TP; HFD+TP10, mice fed HFD (60% fat) supplemented with 10% TP. The HFD+TP10 group showed lower final body weight (34.23 g) than the HFD group (39.41 g), along with decreased epididymal fat weight (p<0.05). In addition, the HFD+TP10 group showed significantly lower serum cholesterol and triglyceride contents (136.32 and 33.20 mg/dL, respectively) that the HFD group (175.68 and 59.52 mg/dL, respectively). Increased serum leptin and insulin levels (66.36 and 1.80 ng/mL, respectively) in mice with HFD-induced obesity could be rescued in mice fed HFD supplemented with 10% TP (35.94 and 1.23 ng/mL, respectively). Additionally, the epididymal fat content and hepatic steatosis area showed a dose-dependent decrease with increase in dietary TP supplementation. The anti-obesity effect of 10% TP was linked to reduced serum trimethylamine-N-oxide levels. These results suggested that 10% TP was effective at inhibiting the accumulation of fat in the serum and tissue, and ameliorating lipid metabolism disorders observed in HFD-fed mice. In addition, such utilization of unmarketable tomato to inhibit obesity-associated pathologies is expected to add value and increase profits in the functional food industry.

꽃송이버섯의 자실체가 고지방과 고콜레스테롤을 급여 한 Sprague-Dawley계 암컷 흰쥐의 지질대사와 비만에 미치는 효과를 조사하기 위해 생후 6주령의 흰쥐에 정상 식이를 급여한 군(ND), 정상 식이에 20%의 돈지(Lard)와 1%의 콜레스테롤을 첨가하여 급여한 군(HFD), HFD 식이에 꽃송이버섯 자실체 분말을 5% 수준으로 첨가하여 급여한 군(HFD+SL), HFD 식이에 simvastatin을 0.3% 수준으로 첨가하여 급여한 군(HFD+SS) 등 4개의 실험군으로 나누어 6주간 실험을 진행하였다. 각각의 실험군 간 체중의 증가율은 HFD+SL군과 HFD+SS군이 HFD군에 비해 유의하게 감소하여 ND군와 유사한 수준을 나타내 HFD 식이에 꽃송이버섯을 첨가하여 급여한 HFD+SL군의 비만이 억제되었다. ND군의 식이섭취량은 HFD군에 비해 유의하게 높았고 HFD+SL군과 HFD+SS군에 비해서는 고도로 유의하게 높았다. 혈청 총콜레스테롤(TC), 저밀도지단백질 콜레스테롤(LDL-C) 및 중성지방(TG)의 농도는 HFD군에 비해 ND군, HFD+SL군 및 HFD+SS군이 유의하게 낮았다. 심혈관계 질환의 위험도를 나타내는 동맥경화지수(AI)와 LDL-C/HDL-C 비율도 HFD군에 비해 ND군, HFD+SL군 및 HFD+SS군이 유의하게 낮아 꽃송이버섯 자실체의 급여가 심혈관계 질환의 발생 위험도를 낮출 수 있은 것으로 나타났다. 알부민, 크레아티닌, 요산 및 총단백질의 농도는 모든 실험군 간 정상적인 수치를 나타냈으나 혈당 농도는 HFD군에 비해 ND군, HFD+SL군, HFD+SS군 모두 유의하게 낮아 꽃송이버섯이 혈당을 낮추는 효과가 있었다. 간 기능 손상의 척도를 나타내는 AST와 ALT 효소의 활성은 모든 실험군 간 유의성은 없었으나 ALP 효소의 농도는 HFD에 비해 ND군 와 HFD+SL군 및 HFD+SS군이 유의하게 낮아 꽃송이버섯을 첨가한 식이의 급여가 흰쥐의 ALP 농도를 유의하게 낮추는 효과가 있었다. 실험 5주와 6주 사이에 배출된 분변의 총 지질과 콜레스테롤의 양을 측정한 결과 HFD+SL 군이 배출한 총 지질과 콜레스테롤의 양이 HFD군과 HFD+SS군에 비해 유의하게 높게 나타나 HFD식이에 함유된 일부의 지질과 콜레스테롤이 꽃송이버섯에 의해 장 내로 흡수되지 않고 분변으로 배출된 것으로 나타났다. 각각의 실험군의 간 조직을 적출하여 oil red O로 염색하고 현미경으로 관찰한 결과 HFD군에서는 심한 지방간이 관찰되었으나 HFD+SS군은 ND군과 같이 지방간이 전혀 관찰되지 않았고 HFD+SL군의 간 조직에서는 소량의 지방 방울이 관찰되어 꽃송이버섯의 자실체에는 비알코올성 지방간을 억제하는 효과가 있는 것으로 나타났다. 따라서 꽃송이버섯 자실체는 고지방과 고콜레스테롤 식이 섭취로 인해 발생하는 체중증가, 혈청의 콜레스테롤과 중성지방 농도 및 비알코올성 지방간의 개선에 효과가 있어 심혈관계 질환과 비만의 예방과 치료에 도움을 줄 수 있을 것으로 판단된다.

Whole grain cereal (WGC)-rich diets provide macronutrients that are important for the regulation of energy metabolism. The current study evaluated whether WGCs had a preventive effect on sarcopenic obesity in high-fat diet (HFD)-induced obese mice. C57BL/6N mice were fed a normal diet (ND), ND+WGC, HFD, and HFD+WGC for 12 weeks. WGCs significantly reduced body weight gain, food efficiency ratio, fat mass, and adipocyte size in HFD-induced obese mice. WGCs attenuated HFD-induced nonalcoholic fatty liver disease by decreasing liver weight and hepatic fat accumulation. In addition, WGCs increased muscle strength and muscle mass in HFD-induced obese mice as well as in ND mice. Taken together, WGCs can be employed as functional food materials for the prevention of sarcopenic obesity by inhibiting fat accumulation and increasing muscle mass.

Metabolic syndrome, including obesity, glucose intolerance and elevated blood pressure, is related to type 2 diabetes and cardiovascular disease. Previous studies have reported the anti-oxidative, anti-inflammatory and anti-diabetic effects of purple corn extract. We investigated the efficacy of purple corn extract (PC) against high-fat diet (HFD)-induced obesity and glucose intolerance, and examined the underlying mechanisms by analyzing expression of proteins and genes involved in glucose regulation and macrophage infiltration. C57BL/6 mice were fed with normal chow diet (ND), or HFD treated with distilled water (DW, control) or PC, for 10 weeks. Although body weights were similar in the HFD-fed groups, we observed a decrease in the liver and epididymal adipose tissue (EAT) weights, and enhanced glucose tolerance test (GTT) results in the PC group, as compared with DW group. Liver showed increased Akt phosphorylation in the PC-treated mice; however, no changes were observed in the EAT, for all groups. In PC-treated mice, decreased macrophage infiltration was seen in the EAT, with a reduced expression of macrophage marker genes. Finally, proinflammatory cytokine gene expressions were decreased by PC in the EAT, and a modest trend for downregulation was observed in the liver. Hence, we conclude that PC may decrease glucose intolerance by increasing the phosphorylation of Akt and reducing the macrophage infiltration into the EAT.

This study was performed to investigate the anti-obesity and anti-lipidemic ability of linalool (LL) in ApoE deficient mice fed a high-fat diet (HFD). Mice were divided into four experimental groups of eight each. Mice in the control group received a basic diet and oral repeated dose of the vehicle only for 12 weeks; mice in the HFD group received a HFD and oral repeated dose of the vehicle only for 12 weeks; and the HFD&LL25 and HFD&LL50 groups received a HFD and oral repeated dose of LL 25 and 50 mg/kg/day for 12 weeks, respectively. Mice in the HFD group showed a significant increase in body weight, spleen weight, and adipose tissue weight, compared with the control group. An increase in the serum levels of aspartate aminotransferase and alanine aminotransferase activities, total cholesterol (T-CHO), triglyceride (TG), and low density lipoprotein cholesterol was also observed in the HFD group. Histopathological examinations showed severe liver injuries, characterized by extensive fatty changes and hepatocyte degeneration/necrosis. On the contrary, oral administration with LL resulted in significantly improved HFD-induced obesity and hyperlipidemia, indicated by a decrease in adipose tissue weight, T-CHO, TG, and histopathological lesions. The results indicate that LL suppressed HFD-induced obesity, hyperlipidemia, hypercholesterolemia, and hepatic steatosis, suggesting that LL might be a promising adjuvant therapy for treatment of these metabolic disorders related to corpulence.

JAZF1 is a 27 kDa nuclear protein containing two putative zinc finger motifs that is associated with diabetes mellitus and prostate cancer according to genomewide association studies; however, little is known about the function of this gene in regulating metabolism. Recent evidence indicates that JAZF1 transcription factors bind to the nuclear orphan receptor TR4 and act as a strong repressor. This receptor regulates PEPCK, the key enzyme in gluconeogenesis, at the transcriptional level. Excess PEPCK expression in mice causes hyperglycemia, hyperinsulinemia, and increased glucose turnover. Therefore, we hypothesized that ectopic expression of Jazf1 may lead to abnormal expression of PEPCK that allow for the metabolic disorder. To elucidate its role in metabolism, we fed the mice with high- or normal- fat diet up to 18 weeks. In the liver tissue of mice, Jazf1 overexpression led to a substantial reduction in the expression of PEPCK. In Jazf1 overexpression mice, weight gain was found to be significantly decreased and increment of blood glucose level also decreased. Our data suggest that Jazf1 plays a critical role in the regulation of energy and lipid homeostasis, and promotes the development of metabolic disorder. Jazf1 may provide a new therapeutic target in the management of obesity, diabetes, and liver steatosis.

Background: An imbalance in energy intake and expenditure can cause obesity, which is a major risk factor for chronic diseases such as heart disease, type 2 diabetes, insulin resistance, cancers and hyperlipidemia. Methods and Results: In this study, we evaluated the anti-obesity effects of a water extract from the young leaves of barley sprout (BS) in 3T3-L1 cells and in high-fat diet (HFD)-induced obese mice (HF). Lipid accumulation measurement indicates that BS markedly inhibited adipogenesis by reducing lipid droplet production in a dose-dependent manner. Furthermore, the mRNA expression of adipogenic transcription factors peroxisome proliferator-activated receptor-γ and fatty acid synthetase, CCAAT/enhancer binding protein-α and fatty acid binding protein 4 in 3T3-L1 cells was significantly inhibited by BS treatment. In an in vivo test, the BSadministered group of HFD-induced mice showed less body weight gain, and lower liver and epididymal white adipose tissue weights. The BS-treated mice showed decreased serum levels of leptin and lipids compared to untreated HFD mice and the levels of adiponectin and the HDL-cholesterol/total cholesterol ratio increased. These results indicate that BS inhibits body fat accumulation by reducing the mRNA expression of lipogenesis transcription factors and increasing serum adipokine concentration in in vitro and in vivo tests. Conclusions: BS reduced high fat diet-induced weight gain and had a positive effect on dyslipidemia.

Obesity is a pro-inflammatory state that contributes to the development of metabolic disorders such as hyperlipidemia, insulin resistance, type 2 diabetes, non-alcoholic fatty liver, and cardiovascular disease. In this study, we evaluated the inhibition of adipogenesis in 3T3-L1 cells and in high-fat diet (HFD)-induced obese mice by Peucedanum japonicum Thunberg L. water extract (PJT). Lipid accumulation measurement indicates that PJT markedly inhibited adipogenesis in a dose-dependent manner. RT-PCR results demonstrated that the mRNA expression of adipogenic transcription factors such as peroxisome proliferator-activated receptor-γ (PPARγ) and CCAAT/enhancer binding protein- α (C/EBPα) in 3T3-L1 cells were significantly down-regulated by PJT treatment. Oral administration of PJT (100, 300, and 500 ㎎/㎏, b.w/daily for 4 weeks) was conducted in high-fat diet induced obese mice and C57BL/6 mice. The PJT-administered group of HFD-induced mice had a lower body weight gain, along with decreased serum levels of glucose, triglycerides, and total cholesterol compared with the control mice, however, the HDL-cholesterol/total cholesterol ratio was increased. Furthermore, the elevated mRNA expression levels of adipogenesis related genes in the white adipose tissue of obese mice were significantly suppressed by PJT. These results indicate that PJT exhibits anti-obesity effects in obese mice by decreasing in serum lipid levels and lipogenesis related gene.